[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

60 Degrees Pharmaceuticals Inc (SXTP)

60 Degrees Pharmaceuticals Inc (SXTP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,122
  • Shares Outstanding, K 2,659
  • Annual Sales, $ 1,410 K
  • Annual Income, $ -7,370 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 2.47
  • Price/Sales 3.06
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.74
  • Number of Estimates 2
  • High Estimate $-0.58
  • Low Estimate $-0.89
  • Prior Year $-5.00
  • Growth Rate Est. (year over year) +85.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +27.87%
on 06/11/26
1.9200 -18.75%
on 07/01/26
+0.1700 (+12.23%)
since 06/09/26
3-Month
1.2200 +27.87%
on 06/11/26
2.4000 -35.00%
on 04/15/26
-0.1800 (-10.34%)
since 04/09/26
52-Week
1.2200 +27.87%
on 06/11/26
10.7712 -85.52%
on 07/10/25
-8.2800 (-84.15%)
since 07/09/25

Most Recent Stories

More News
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease Agreement...

SXTP : 1.5600 (+0.65%)
SXTPW : 0.0231 (-22.22%)
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing...

SXTP : 1.5600 (+0.65%)
SXTPW : 0.0231 (-22.22%)
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

License allows the Company to commence large-scale extraction of castanospermine from the seeds of  Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter...

SXTP : 1.5600 (+0.65%)
SXTPW : 0.0231 (-22.22%)
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-blind,...

SXTP : 1.5600 (+0.65%)
SXTPW : 0.0231 (-22.22%)
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ:  SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious...

SXTP : 1.5600 (+0.65%)
SXTPW : 0.0231 (-22.22%)
RedChip's Biotech Investor Conference Replays Now Available

ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...

NXL : 0.4520 (+8.89%)
BIVI : 2.24 (+2.75%)
SXTP : 1.5600 (+0.65%)
BFRG : 0.7370 (+8.43%)
LTRN : 3.35 (+8.06%)
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website

Travelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway Health telehealth platform WASHINGTON, April 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees...

SXTP : 1.5600 (+0.65%)
SXTPW : 0.0231 (-22.22%)
Infrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / April 2, 2026 / RedChip Companies will air interviews with Infrastructure Capital Advisors, LLC (NYSE:SCAP)(NYSE:PFFA)(NYSE:BNDS) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP)...

BNDS : 50.68 (+0.12%)
PFFA : 20.97 (+0.33%)
SXTP : 1.5600 (+0.65%)
SCAP : 38.27 (+1.14%)
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference

ORLANDO, FL / ACCESS Newswire / April 2, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...

NXL : 0.4520 (+8.89%)
BIVI : 2.24 (+2.75%)
SXTP : 1.5600 (+0.65%)
BFRG : 0.7370 (+8.43%)
LTRN : 3.35 (+8.06%)
60 Degrees Pharmaceuticals Announces 2025 Annual Results

FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees...

SXTP : 1.5600 (+0.65%)
SXTPW : 0.0231 (-22.22%)

Business Summary

60 Degrees Pharmaceuticals Inc. specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. 60 Degrees Pharmaceuticals Inc. is based in WASHINGTON.

See More

Key Turning Points

3rd Resistance Point 1.7067
2nd Resistance Point 1.6533
1st Resistance Point 1.6067
Last Price 1.5600
1st Support Level 1.5067
2nd Support Level 1.4533
3rd Support Level 1.4067

See More

52-Week High 10.7712
Fibonacci 61.8% 7.1226
Fibonacci 50% 5.9956
Fibonacci 38.2% 4.8686
Last Price 1.5600
52-Week Low 1.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.